Skip to content

Inventiva

US · IVA #3421 by market cap Listed 2020
3.37 -0.10 -2.75%
Live - 5344 symbols - heartbeat 166s ago · 2026-10-08 08:59
Pre-market 3.30 -1.93%
After-hours 3.37 0.00%
Overnight 3.39 +0.74%
Market cap
794.93M
P/B
12.02
EPS
-2.13
Reader sentiment Are you bullish or bearish on IVA?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 12.02 Expensive vs history 100th percentile
5-year average -15.03 · #451 of 513 in Biotechnology
P/E ratio -5.63 Cheap vs history 14th percentile
5-year average -2.82 · forward -3.82
P/S ratio 14,496.33 Expensive vs history 100th percentile
5-year average 230.11 · forward 250.30 · #376 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Inventiva (IVA) 794.93M -5.63 12.02 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value5.16 Economic moatNarrow UncertaintyVery High

Trading 53.3% below Morningstar's fair value estimate.

Fair value

Inventiva SA is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 35% discount to our quantitative fair value estimate of $5.16 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 0.8 lies in the bottom 20% globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, for example, falls in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 08:59:17 · For reference only, not investment advice and not tailored to your situation.